Navigation Links
Review offers insight on managing surgical patients who are taking new drugs to prevent blood clots
Date:4/28/2014

New oral anticoagulant drugs that treat and prevent clots offer a much-needed alternative to warfarin, which has been used for more than 6 decades and has serious shortcomings. A new article published in BJS (British Journal of Surgery) gives an overview of the major clinical trials and recommendations related to these new agents and will serve as a practical guide for their use in patients who require planned or emergency surgery.

Warfarin has been the drug of choice to control blood clots in a variety of patients, including people with certain types of irregular heartbeats, people with prosthetic heart valves, and people who have suffered heart attacks. Unfortunately, warfarin has serious side-effects, requires frequent monitoring to reduce the risk of bleeding, and has interactions with multiple drugs and foods. New oral anticoagulant drugsApixaban, Dabigatran, and Rivaroxaban offer safer alternatives to warfarin, but there are currently no markers for measuring activity levels of the drugs and there are no antidotes to reverse or neutralize their effects.

Aida Lai, MBChB, of the North Bristol NHS Trust in the UK, and her colleagues searched the medical literature and analysed studies published between January 2000 and January 2014 that reported on the use of new oral anticoagulant drugs. "As these drugs are still relatively new in the market, knowledge about how they work and their associated bleeding risks are still limited in the medical and surgical community," said Dr Lai. "Our review covers recommendation for the discontinuation of new oral anticoagulant drugs before surgical procedures and resuming of these drugs after procedures." The review also notes that because the drugs are eliminated by the kidneys, they require dose reductions dependent on a patient's kidney function. Also, new oral anticoagulants are not recommended in patients with severe liver dysfunction. And because the three drugs have somewhat different properties, one of the drugs may be better suited to a particular patient than the others.

"It is anticipated that in the near future these drugs would replace warfarin to a large extent," said Dr Lai. "Therefore our article is highly relevant to surgeons and any medical professional treating patients on these drugs."


'/>"/>

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
201-748-6358
Wiley
Source:Eurekalert

Related medicine news :

1. McCullers reviews influenza, bacterial superinfections in Nature Reviews Microbiology
2. Internists review progress, challenges and opportunities
3. Do patient decision support interventions lead to savings? A systematic review
4. CU-built software uses big data to battle forgetting with personalized content review
5. PowerSteering from Upland Software Earns High Marks in Review by GetApp
6. Vision Without Glasses: Review Released by ReviewsGod.com
7. Total Balance Men’s: Review Released for Xtend-Life’s Comprehensive Dietary Supplement for Men
8. Workout Finishers Review – How Workout Finishers Helps People To Get A Fit Shape – Vinaf.com
9. 14 Day Rapid Fat Loss Plan Review–How To Get Rid Of Fat With 14 Day Rapid Fat Loss – Vinaf.com
10. The Cleft Palate–craniofacial Journal Marks 50 Years of Research With an Ethical Review
11. Regenstrief and IU review finds lack of delirium screening in the emergency department
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... lecture to primary eye care practitioners on the latest breakthroughs in the prevention, ... Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Neil H. Greco ... planning assistance to communities throughout the region, is launching a charity drive to raise ... is by far the deadliest killer in America, and is responsible for 1 in ...
(Date:1/17/2017)... Los Gatos, CA (PRWEB) , ... January 17, 2017 , ... ... today announced the results of a double blind clinical study for its dental gel ... to a leading national brand of toothpaste containing triclosan. The study was conducted at ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... from two offices in Tyler, has announced the latest beneficiary of their thriving ... Network, a nonprofit organization dedicated to fulfilling the dreams of terminally ill patients. ...
(Date:1/17/2017)... ... ... Today, FloSports , a global leader in live digital sports and original ... long-term extension of their media partnership. The partnership, which began in 2013, will now ... events exclusively on FloWrestling.com as well as usage of the FloArena meet management software ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 2017 In China , we ... the Upgrade of China,s Healthy Strategy ... Plan for Economic and Social Development of the ... and the state council of the People,s Republic ... emerging industry development plan, identifying medical devices as one of ...
(Date:1/18/2017)... Jan. 18, 2017  Tarix Orphan LLC today announced ... a Rare Pediatric Disease (RPD) designation for the company,s ... Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. There ... is limited to supportive care. "The RPD ... Designation previously granted by the FDA in this indication," ...
(Date:1/18/2017)...  Robust competition in the private marketplace is resulting in ... to a new study by the Berkeley ... to examine the share of prescription medicine spending retained ... health plans and other stakeholders in the supply chain. ... show what happens when the list price of a ...
Breaking Medicine Technology: